Qurient Co Ltd
115180
Company Profile
Business description
Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.
Contact
C-dong 8th Floor, 242, Pangyo-ro
Bundang-gu
Seongnam-siGyeonggi-do13487
KORT: +82 3180601600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
33
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.40 | 22.00 | -0.24% |
| CAC 40 | 7,813.97 | 36.46 | -0.46% |
| DAX 40 | 24,292.55 | 51.73 | 0.21% |
| Dow JONES (US) | 44,766.33 | 243.96 | -0.54% |
| FTSE 100 | 9,144.95 | 83.46 | 0.92% |
| HKSE | 25,667.18 | 129.11 | 0.51% |
| NASDAQ | 21,059.31 | 39.29 | 0.19% |
| Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
| NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
| S&P 500 | 6,367.96 | 9.05 | 0.14% |
| S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
| SSE Composite Index | 3,605.73 | 23.43 | 0.65% |